Ofloxacin Ophthalmic Solution USP, 0.3%

FDA Drug Profile — Ofloxacin

Ofloxacin Ophthalmic Solution USP, 0.3% is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including Ofloxacin. Available dosage form: solution/ drops.

Drug details

Generic Name
Ofloxacin Ophthalmic Solution USP, 0.3%
Brand Names
Ofloxacin
Application Number
ANDA217904
Sponsor
Caplin Steriles Limited
NDC Codes
3
Dosage Forms
SOLUTION/ DROPS
Routes
OPHTHALMIC
Active Ingredients
OFLOXACIN

Indications and Usage

INDICATIONS & USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens Efficacy for this organism was studied in fewer than 10 infections Streptococcus pneumoniae Anaerobic species: Propionibacterium acnes

Warnings

WARNINGS NOT FOR INJECTION. Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye. There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin. If an allergic reaction to ofloxacin occurs, discontinue the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management, including intubation should be administered as clinically indicated.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.